source
- Roche's Lunsumio clears Phase 3 hurdle, paving way for broader label in indolent lymphomaRoche announced that its T cell engager Lunsumio successfully met the primary endpoints in a Phase 3 study of a slow growing blood cancer. The trial, conducted in patients with indolent lymphoma,…
- North Immunology to go public via reverse merger with Aethlon, targeting eczema marketNorth Immunology, an early-stage biotech developing a dual-acting antibody for eczema, announced plans to become a public company through a reverse merger with Aethlon Medical. The transaction wil…